Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
83.67
-3.49 (-4.00%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Dianthus Therapeutics Revenue
In the year 2025, Dianthus Therapeutics had annual revenue of $2.04M, down -67.35%. Dianthus Therapeutics had revenue of $284.00K in the quarter ending December 31, 2025, a decrease of -78.58%.
Revenue (ttm)
$2.04M
Revenue Growth
-67.35%
P/S Ratio
2,237.59
Revenue / Employee
$22,130
Employees
92
Market Cap
4.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.04M | -4.20M | -67.35% |
| Dec 31, 2024 | 6.24M | 3.41M | 120.63% |
| Dec 31, 2023 | 2.83M | -3.59M | -55.96% |
| Dec 31, 2022 | 6.42M | 4.94M | 334.76% |
| Dec 31, 2021 | 1.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.03B |
| Apellis Pharmaceuticals | 1.00B |
| Caris Life Sciences | 812.03M |
| Corcept Therapeutics | 761.41M |
| Amicus Therapeutics | 634.21M |
| TG Therapeutics | 616.29M |
| Ligand Pharmaceuticals | 268.09M |
| Crinetics Pharmaceuticals | 7.70M |
DNTH News
- 22 days ago - Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 7 weeks ago - Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering - GlobeNewsWire
- 7 weeks ago - Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering - GlobeNewsWire
- 7 weeks ago - Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism - Benzinga
- 7 weeks ago - Dianthus Therapeutics Transcript: Study result - Transcripts
- 7 weeks ago - Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - GlobeNewsWire